While glyburide has shown inhibitory effects both in vitro and in vivo against NLRP3 activation, its high doses in vivo can lead to hypoglycemia, limiting its use for T2D treatment [88]. The gene discussed is NLRP3; the disease is type 2 diabetes mellitus.